Category: Home

Adaptive antimicrobial materials

Adaptive antimicrobial materials

Feng W. Murray, J. Trade-offs between antimivrobial toxicity and benefit in the multi-antibiotic resistance system underlie optimal growth of E. In addition, P. Binhi, V. Adaptive antimicrobial materials

Araptive efficient host immune system, the Innovative approaches to skin rejuvenation mwterials can antimicrobiql rapidly occupied by bacteria, resulting in infection Innovative approaches to skin rejuvenation, implant antjmicrobial, and even death of the patients.

It Innovative approaches to skin rejuvenation difficult to cope antimicrrobial these problems because bacteria exhibit complex adhesion mechanisms materixls the implants antimicrpbial vary according to bacterial strains. Different biomaterial coatings have been produced to release antibiotics to Aadptive bacteria.

However, antibiotic Mental health occurs Adaptive antimicrobial materials frequently. This review is focused on the development of highly efficient and specifically targeted biomaterials that release the antimicrobial agents or respond to bacteria on demands in body.

The mechanisms of bacterial adhesion, biofilm formation, and antibiotic resistance are discussed, and the released substances accounting for implant infection are described.

Strategies that have been used in past for the eradication of bacterial infections are also discussed. Different types of stimuli can be triggered only upon the existence of bacteria, leading to the release of antibacterial molecules that in turn kill the bacteria.

In particular, the toxin-triggered, pH-responsive, and dual stimulus-responsive adaptive antibacterial biomaterials are introduced.

Finally, the state of the art in fabrication of dual responsive antibacterial biomaterials and tissue integration in medical implants is discussed. Keywords: Anti-foulings; Antibacterial; Antibiotic resistance; Biofilm; Tissue engineering.

Publication types Review.

: Adaptive antimicrobial materials

Supplementary files Figure 3 shows the TEM images of BTF and BTF coated with NF nanoceramics calcined at °C. Urbanowicz P. The analyzer was pre-calibrated using gas tanks with known CO 2 concentration. Llanes C. The molecular mechanism linking mutations within EF-G to increased aminoglycoside resistance remains unclear.
How Antimicrobial Resistance Happens

Nature , 32— Costerton, J. Mechanism of electrical enhancement of efficacy of antibiotics in killing biofilm bacteria. Agents Chemother. Dobson, J. Remote control of cellular behaviour with magnetic nanoparticles. Dong, Y. AiiA, an enzyme that inactivates the acylhomoserine lactone quorum-sensing signal and attenuates the virulence of Erwinia carotovora.

Quenching quorum-sensing-dependent bacterial infection by an N-acyl homoserine lactonase. Nature , — Dubois, J. Ferroelectric polymers: chemistry, physics, and applications. Edited by Hari Singh Nalwa, Marcel Dekker, New York , XII, pp. Fayaz, A.

Biogenic synthesis of silver nanoparticles and their synergistic effect with antibiotics: a study against gram-positive and gram-negative bacteria. Nanomedicine 6, — Fernandes, C. Advances in magnetic nanoparticles for biomedical applications.

Fleming, S. Nobel Lecture on Penicillin. Gall, I. The effect of electric fields on bacterial attachment to conductive surfaces. Soft Matter 9, — Gera, N. Kinetics and mechanism of bacterial inactivation by ultrasound waves and sonoprotective effect of milk components. Food Sci. Ghasemi-Mobarakeh, L.

Application of conductive polymers, scaffolds and electrical stimulation for nerve tissue engineering. Tissue Eng. Ghodbane, S. Bioeffects of static magnetic fields: oxidative stress, genotoxic effects, and cancer studies.

Biomed Res. Gould, I. New antibiotic agents in the pipeline and how they can help overcome microbial resistance. Virulence 4, — Graczyk, E. The neural basis of perceived intensity in natural and artificial touch.

Guduru, R. Magnetic field-controlled release of paclitaxel drug from functionalized magnetoelectric nanoparticles. Particle Particle Syst. Hajipour, M. Antibacterial properties of nanoparticles. Trends Biotechnol. Hazan, Z. Effective prevention of microbial biofilm formation on medical devices by low-energy surface acoustic waves.

Hentzer, M. Pharmacological inhibition of quorum sensing for the treatment of chronic bacterial infections. Hong, S. Effect of electric currents on bacterial detachment and inactivation.

Howie, H. The N. gonorrhoeae type IV pilus stimulates mechanosensitive pathways and cytoprotection through a pilT-dependent mechanism.

PLoS Biol. Ichinohe, T. Microbiota regulates immune defense against respiratory tract influenza A virus infection. Ikehata, M. Mutagenicity and co-mutagenicity of static magnetic fields detected by bacterial mutation assay.

Istanbullu, O. Electrochemical biofilm control: mechanism of action. Biofouling 28, — Ivanova, K. Quorum-quenching and matrix-degrading enzymes in multilayer coatings synergistically prevent bacterial biofilm formation on urinary catheters.

Interfaces 7, — Enzyme multilayer coatings inhibit Pseudomonas aeruginosa biofilm formation on urinary catheters. Méndez-Vilas Badajoz: Formatex , — Kalia New Delhi: Springer , — Jørgensen, P. Use antimicrobials wisely. Justin, T. Antibacterial effect of zinc oxide nanoparticles combined with ultrasound.

Nanotechnology Kim, K. Fecal microbiota transplantation: an update on clinical practice. Kociolek, M. Quorum-sensing inhibitors and biofilms. Anti Infect.

Agents Med. Kudr, J. Magnetic nanoparticles: from design and synthesis to real world applications. Nanomaterials Laxminarayan, R.

Un high-level meeting on antimicrobials — what do we need? Lancet , — Li, S. Magnetic field exposure induces DNA degradation. Mah, T.

Mechanisms of biofilm resistance to antimicrobial agents. Trends Microbiol. Mao, H. A sensitive, versatile microfluidic assay for bacterial chemotaxis. Martins, P. Polymer-based magnetoelectric materials.

Miller, E. The penicillins: a review and update. Women's Health 47, — Ni, N. Inhibitors and antagonists of bacterial quorum sensing. Paces, W. Application of sub-micrometer vibrations to mitigate bacterial adhesion.

Paluch, E. Mechanotransduction: use the force s. BMC Biol. Pérez, R. Naturally and synthetic smart composite biomaterials for tissue regeneration. Drug Deliv. Persat, A. The mechanical world of bacteria. Cell , — Poortinga, A. Electric field induced desorption of bacteria from a conditioning film covered substratum.

Preethi Soundarya, S. Bone tissue engineering: scaffold preparation using chitosan and other biomaterials with different design and fabrication techniques. Pu, J. EGF receptor signalling is essential for electric-field-directed migration of breast cancer cells. Cell Sci.

Qazi, T. Tissue engineering of electrically responsive tissues using polyaniline based polymers: a review. Biomaterials 35, — Qian, Z. The effect of ultrasonic frequency upon enhanced killing of P. aeruginosa biofilms.

Rasko, D. Anti-virulence strategies to combat bacteria-mediated disease. Drug Discov. Rasmussen, B. Filamentous microfossils in a 3,million-year-old volcanogenic massive sulphide deposit. Rasmussen, T. Quorum sensing inhibitors: a bargain of effects. Microbiology , — Reardon, S.

Resistance to last ditch antibiotic has spread further than anticipated. Rediske, A. Ultrasonic enhancement of antibiotic action on Escherichia coli biofilms: an in vivo model. Relman, D. Microbiology: learning about who we are. Rezwan, K. Biomaterials 27, — Ribeiro, C. The stages are: 1 Evolve resistant populations in a bioreactor under polymorphic selection conditions; 2 Identify the frequency and order of mutations correlated with antibiotic resistance as a function of time; 3 Identify the genotypes of end-point isolates to establish genetic linkages; 4 Validate the effect of mutations by physicochemical characterization; 5 Rank candidates for potential drug development.

aeruginosa , PAO1 was evolved to colistin resistance using our quantitative experimental evolution approach in our modified bioreactor. aeruginosa as determined by MIC Interpretive standards set by the Clinical and Laboratory Standards Institute CLSI.

The mutation in MutS resulted in a strong hypermutator phenotype. Hypermutator phenotypes in P. aeruginosa have been observed at high frequency in clinical isolates of sputum from cystic fibrosis patients.

In the presence of this rapid mutation rate, mutations specific to resistance were seen to accumulate in the two-component system, pmrAB , which has been clinically linked to colistin resistance. The deconvolution of all the mutations within this hypermutator will be discussed in later work.

PmrAB is a two-component regulatory system that activates downstream lipopolysaccharide modification systems in response to cationic antimicrobial peptides.

Quantitative analysis of the metagenomic deep sequencing data for each daily, heterogenous sample using Breseq 25 allowed us to identify the frequency at which mutations in pmrAB rose and spread throughout the population Figure 3. Based on the predicted domain structure of the membrane bound sensor kinase PmrB, 18 single nucleotide polymorphisms leading to amino acid substitutions in the transmembrane domains L17P, L18P, LP, LP , in the periplasmic domain D47G, VM , in the HAMP linker domain present in Histidine kinases, Adenyl cyclases, Methyl-accepting proteins and Phosphatases VA and in the C-terminal ATP binding domain AP, FL were observed in our evolved population.

Mutations in these domains have also been observed in colistin-resistant clinical isolates 18 , 26 , 27 as well as lab-adapted colistin-resistant strains of P.

Figure 3 traces the frequencies of these mutations and the point at which they arose during the experiment. This suggests that there may be other mutations that occur prior to the pmrAB mutations which predispose PAO1 to colistin resistance.

One unintentional benefit of hypermutators is that they can provide a very extensive survey of the entire adaptive landscape and thus provide a comprehensive catalog of mutations that may facilitate resistance.

Frequencies of mutant alleles associated with colistin resistance in P. aeruginosa PAO1. Mutations in the pmrAB operon were identified by analysis of whole genome sequencing data obtained from each daily population collected from the bioreactor.

The corresponding day on which the mutation is observed is on the x axis. The gray dashed lines represent the distinct colistin concentrations the culture was exposed to during evolution. The mutations on the right are the amino acid changes in the protein caused by single nucleotide polymorphisms SNPs in the corresponding gene pmrA or pmrB.

Note that some mutations such as pmrB AP have early success but then become extinct as other more successful pmrA alleles confer greater success to drug selection. Although there are several positions on the pmrB gene that developed single nucleotide polymorphisms during the course of adaptation, not all of them persisted till the end.

The final end-point isolates we sequenced had only one L18P out of the nine mutations observed in the daily populations. Our results suggest that our approach provides a fairly comprehensive survey of all the mutations appearing throughout the course of adaptation and limits the role of population bottlenecks in limiting the accessible evolutionary trajectories.

The modified bioreactor we use for adaptation provides several advantages over traditional serial transfer evolution experiments.

Many clinically significant bacteria form thick biofilms and bioreactor culturing can select for this formation. This long-term establishment of biofilm more accurately mimics the natural ecology that many of these organisms create. The organism studied in this work, P.

aeruginosa to colistin. Additionally, it is clear that the evolutionary trajectories obtained from these studies do not address the molecular mechanisms of pathogenesis. Pathogenesis requires an appropriate host or host cell line. In vitro experimental evolution is very informative, however, in determining the molecular basis for antibiotic resistance.

Adaptive mutations conferring antibiotic resistance have very strong effects on the fitness of the organism that typically far out-weigh those of adapting to the bioreactor growth conditions since we do not limit critical resources such as carbon and nitrogen. Biofilm build up in the bioreactor vessel during evolution of P.

The bioreactor design favors the development of strong biofilms. Since the evolution of the populations takes place over weeks in a single vessel, those adaptive alleles that favor biofilm formation have a selective advantage as they can adhere to surfaces and not be removed as new media is added to maintain a constant exponentially growing planktonic phase.

Acinetobacter , enterococci and Pseudomonas have all exhibited strong biofilm formation in this experimental system. The bioreactor also maintains a continuous culture at its fastest growth rate while slowly increasing the antibiotic concentration in an empirically designed, stepwise manner.

One of the major advantages of evolving resistance in a bioreactor is the evolution of a highly polymorphic population to study the subtle nuances of antibiotic resistance. This polymorphism arises from the large culture volume, continuous logarithmic growth, reduced bottleneck and growth in sub-inhibitory concentrations of antibiotic.

Bioreactor experiments are carried out with culture volumes ranging from 0. Flask transfer experiments also enter stationary phase each day, reducing the number of doublings.

While P. aeruginosa can only achieve 6—8 generations before reaching stationary phase in batch culture when growing in a rich medium, it experiences roughly 20 generations every day in the bioreactor.

This increase in replication allows for a more thorough survey of possible mutations across the genome. Quantitative analysis of the deep sequencing data obtained from the daily populations provides us with a comprehensive list of all mutations occurring in the population during the process of evolution and their relative frequencies in the population.

It also allows us to look at the rise and fall of genotypes that help in the early adaptation of the population but may not persist at higher antibiotic concentrations due to a more favorable mutation arising and taking over the population.

This is clear in Figure 3 where early mutations like AP and LP within PmrB are seen at high frequencies during early adaptation but are replaced by other mutations at higher drug concentration.

The appearance and persistence of a mutation relies on the fine balance between the resistance conferred by that mutation and the fitness cost associated with it. From our analysis, we can capture these unsuccessful mutations, which serve as progenitors for the more successful lineages.

Having knowledge of these early mutations is useful in the clinic. With the decreasing cost of whole genome sequencing, clinicians are moving towards the sequencing approach to characterize pathogenic isolates from patients. Knowing which mutations predispose cells to becoming resistant to a particular drug is important information when deciding what antibiotics to administer as treatment.

An essential component of our analysis is the establishment of the order of mutations as well as their frequency Figure 3. Targets for potential drug development are those identified in these critical first steps towards resistance.

Work performed by C. Miller et al. faecalis shows that mutations specific to the liaFSR operon serve as an essential opening step to all the successful evolutionary trajectories leading to resistance.

In another study by K. Beabout et al. showing the evolution of tigecycline TGC resistance in E. faecalis , metagenomic deep sequencing helped identify an increase in transconjugation that lead to the widespread presence of transposon Tn, containing the TGC resistance gene, tetM.

baumannii to TGC resistance. baumannii in the clinic, as well as in our bioreactor evolved populations of P. The sheer number of mutations acquired in hypermutator populations poses a serious challenge for analysis. Metagenomic data from the daily populations as well as frequency data and statistical analysis were essential to identifying the key mutations associated with resistance in this complex genomic background.

A holistic approach that uses experimental evolution, metagenomic deep sequencing and in vitro biochemistry is also very useful for deconstructing complex strategies of antibiotic resistance.

The next step in the quantitative experimental evolution pipeline is the validation of targets identified from genome sequence analysis. However, many bacteria do not possess the genetic tools necessary for gene validation. Also, the epistatic relations between multiple adaptive alleles can prove to be nearly impossible as even five mutations will generate combinations of potential pair-wise interactions.

The order of mutations from our time frequency metagenomics can help to establish the epistatic relationship of complex evolutionary trajectories. However, a combination of in vitro biochemistry, biophysics and modeling can be used to link physicochemical measurements to predictions of phenotypes such as drug resistance.

Measured physicochemical data also provide vital information for the drug design process. From previous studies in our lab on daptomycin resistance in E. faecalis , 12 we showed that the LiaFSR three component system was crucial in conferring resistance.

By studying the LiaR protein, we determined that the adaptive mutation in LiaR causing resistance DN , constitutively activated the protein and hence, its regulon.

These two proteins form putative targets for drug design. Whenever a mutation confers antibiotic resistance, this gene and the protein it encodes for can serve as a potential target for adjuvant co-drug development to limit resistance.

For example, after identifying the upregulation of the liaFSR system as a major player in daptomycin resistance in E. faecalis , 12 we adapted strains of E.

faecium with liaR deletions to daptomycin resistance. These strains evolve resistance two times slower than the original, susceptible ancestor unpublished , suggesting that administering a drug to inhibit liaR during daptomycin treatment would increase the likelihood of successful treatment.

While bacteria will continue to evolve resistance mechanisms, even to this two-pronged attack, the efficacy of current antibiotics would be extended while novel antimicrobials are developed.

Additionally, the physicochemical assays that are used to assess how a protein promotes resistance can often be used as high-throughput assays for drug discovery. Quantitative experimental evolution also determines important adaptive mutations that arise early in treatment.

By a more strategic administration of antibacterials, we can slow the emergence and subsequent spread of resistance in pathogens.

The wealth of data derived from our adaptive pipeline provides multiple approaches to extending the efficacy of current antibiotics and potentially slowing the rate at which resistance is observed in the clinic. Using quantitative experimental evolution as a drug development pipeline, we are able to successfully recapitulate resistance mutations observed in the clinic as well as predict resistance mutations before they are observed.

The CDC has classified pathogens based on their threat level and some of the pathogens categorized as serious threats include Acinetobacter, enterococci and Pseudomonas. This method also allows us to identify how likely a therapy will fail, which in turn, will lead to the design of new treatment strategies, such as adjuvant molecules that may prevent or postpone development of resistance, or combination therapies that can restore susceptibility to current drugs.

This article is dedicated to K. His passion and dedication as a scientist are unmatched. A great colleague and an outstanding leader in the field of chemistry. Claudia Zampaloni, Patrizio Mattei, … Kenneth A.

Felix Wong, Erica J. Zheng, … James J. Álvaro Rodríguez del Río, Joaquín Giner-Lamia, … Jaime Huerta-Cepas. Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States, Accessed on 3 August Boucher, H. et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America.

Article Google Scholar. Rice, L. Federal funding for the study of antimicrobial resistance in nosocomial pathogens: no ESKAPE. Munoz-price, L. Emergence of resistance to daptomycin during treatment of vancomycin-resistant Enterococcus faecalis infection.

Barrick, J. Genome dynamics during experimental evolution. Article CAS Google Scholar. Baym, M. Spatiotemporal microbial evolution on antibiotic landscapes. Science , — Toprak, E. Evolutionary paths to antibiotic resistance under dynamically sustained drug selection. Zhang, Q. Acceleration of emergence of bacterial antibiotic resistance in connected microenvironments.

Hammerstrom, T. Acinetobacter baumannii repeatedly evolves a hypermutator phenotype in response to tigecycline that effectively surveys evolutionary trajectories to resistance.

PLoS ONE 10 , e Beabout, K. Rampant parasexuality evolves in a hospital pathogen during antibiotic selection. Arias, C. Genetic basis for in vivo daptomycin resistance in enterococci. Miller, C. Adaptation of Enterococcus faecalis to daptomycin reveals an ordered progression to resistance.

Agents Chemother. Li, X. Rapid emergence of high-level tigecycline resistance in Escherichia coli strains harbouring blaNDM-5 in vivo. Agents 47 , — Niebel, M. Different biomaterial coatings have been produced to release antibiotics to kill bacteria.

However, antibiotic resistance occurs very frequently. This review is focused on the development of highly efficient and specifically targeted biomaterials that release the antimicrobial agents or respond to bacteria on demands in body. The mechanisms of bacterial adhesion, biofilm formation, and antibiotic resistance are discussed, and the released substances accounting for implant infection are described.

Adaptive antibacterial biomaterial surfaces and their applications

Antimicrobial resistance happens when germs like bacteria and fungi develop the ability to defeat the drugs designed to kill them. Resistant infections can be difficult, and sometimes impossible, to treat.

Antimicrobial resistance is a naturally occurring process. However, increases in antimicrobial resistance are driven by a combination of germs exposed to antibiotics and antifungals, and the spread of those germs and their resistance mechanisms.

Antimicrobial resistance does not mean our body is resistant to antibiotics or antifungals. It means the bacteria or fungi causing the infection are resistant to the antibiotic or antifungal treatment. Antibiotics and antifungals save lives, but their use can contribute to the development of resistant germs.

Antimicrobial resistance is accelerated when the presence of antibiotics and antifungals pressure bacteria and fungi to adapt. Antibiotics and antifungals kill some germs that cause infections, but they also kill helpful germs that protect our body from infection.

The antimicrobial-resistant germs survive and multiply. These surviving germs have resistance traits in their DNA that can spread to other germs.

To survive, germs can develop defense strategies against antibiotics and antifungals called resistance mechanisms. Bacteria and fungi can carry genes for many types of resistance. When already hard-to-treat germs have the right combination of resistance mechanisms, it can make all antibiotics or antifungals ineffective, resulting in untreatable infections.

Alarmingly, antimicrobial-resistant germs can share their resistance mechanisms with other germs that have not been exposed to antibiotics or antifungals. This table gives a few examples of defense strategies used to resist the effects of antibiotics or antifungals.

Example: Gram-negative bacteria have an outer layer membrane that protects them from their environment. These bacteria can use this membrane to selectively keep antibiotic drugs from entering. Example: Some Pseudomonas aeruginosa bacteria can produce pumps to get rid of several different important antibiotic drugs, including fluoroquinolones, beta-lactams, chloramphenicol, and trimethoprim.

Example: Some Candida species produce pumps that get rid of azoles such as fluconazole. Example: Klebsiella pneumoniae bacteria produce enzymes called carbapenemases, which break down carbapenem drugs and most other beta-lactam drugs.

The two layers were incorporated with Schiff base structures, which could be broken by the metabolism of bacteria. Under normal and mild infection conditions, PU-PQ-PEG showed excellent antifouling and biocompatible properties against proteins and bacteria.

When serious infection occurred and bacteria colonized on the PU-PQ-PEG surface, the bacteria could trigger the self-adaptive antifouling-bactericidal switching of the surface.

Furthermore, the self-adaptive antibacterial properties of PU-PQ-PEG were also confirmed by an in vitro circulating model to simulate hydrodynamic conditions. PU-PQ-PEG showed self-adaptive antibacterial performances both under static and hydrodynamic conditions.

The results of animal experiments also demonstrated the in vivo anti-infection performance. The present work will provide a promising strategy for developing antibacterial surfaces of catheter materials with hemocompatibility.

Zhang, X. Zhang, Y. Zhao, X. Ding, X. Ding, B. Yu, S. Duan and F. Xu, Biomater. To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page. If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given.

Read more about how to correctly acknowledge RSC content. Fetching data from CrossRef. We use a system of stochastic differential equations see Supporting Information to model the single-cell dynamics of the EPRN shown in Fig.

Validation and parameter calibration for this system were done by comparing our simulations with experimental data from E. coli wild-type cells and ΔtolC mutant strains [ 30 ] see S1 Text , S1 and S2 Tables and S2 and S3 Figs.

The efflux of antibiotics depends on two main parameters: the transcription rate β 0 of the EPRN operon, which ultimately affects the amount of available pumps, and the pump efficiency ε I that controls how much antibiotic the pumps can expel at a certain time.

We will see later that by introducing cell-to-cell variability and mother-daughter correlations in these two parameters, highly resistant populations can arise.

Importantly, due to the large size of the parameter space, we do not perform an exhaustive parameter search to determine the complete regions over which our results hold. Rather, in S1 Table we present a set of parameters that qualitatively reproduce the experimental observations.

Nonetheless, in the Supporting Information we provide a sampling of a wide region of the parameter space for which our results hold see S1 Text and S4 and S5 Figs. The population consists of a set of replicating cells, each one represented by a copy of the system of equations governing the dynamics of the EPRN formally presented in the SI.

Each cell runs internally its own system of equations independently from other cells. These cells will grow or die depending on their internal concentration of nutrients and antibiotics, respectively.

Cell-to-cell variability is implemented by slightly changing the two parameters that most affect the capability of the pumps to reduce the internal concentration of antibiotics. One such parameter is the efficiency ε I of the efflux pumps.

A high efficiency will correspond to a decreased toxicity of the antibiotic, which is due to pumps operating more rapidly or with greater specificity.

We assume that changes in ε I are caused by genetic mutations. However, since mutations alone cannot account for the rapid emergence of adaptive resistance [ 1 , 3 , 4 , 6 ], we also implement variability in the transcription rate β 0 of the EPRN operon.

As stated in the introduction, we assume that cell-to-cell variations of this parameter are caused by epigenetic processes, most likely methylation [ 1 , 14 — 17 ]. It is known that different methylation patterns can produce different transcription rates by changing the DNA binding affinity of some transcription factors [ 14 — 17 ].

We found 12 DAM methylation sites GATC in the regulatory operon of the AcrAB-TolC efflux pump system in E. coli see SI. Each site can be in two states: either it is methylated or it is not. As there are several possible patterns, we will assume that β 0 the transcription rate changes as a continuous variable.

However, this assumption is not crucial. We will see later that even under this scenario in which the values of β 0 are discrete and finite, the same qualitative results are obtained. Cells with different values of β 0 will produce pumps at different rates, which in turn affect their survival.

Variability in the population is then introduced by selecting, for each cell, the parameters β 0 and ε I from Gaussian distributions G μ β , σ β and G μ ε , σ ε , respectively in each case μ is the mean and σ 2 is the variance. On the other hand, inheritance is implemented by correlating the mean values of these Gaussians across generations.

To illustrate the inheritance mechanism in our model, let us consider the i th cell at generation t , which has a transcription rate β 0 i , t. In other words, at each generation and for each cell, β 0 is drawn from a Gaussian distribution G μ β , σ β whose average μ β is the value of β 0 previously owned by the corresponding mother.

This mechanism, which clearly correlates the parameters β 0 along cell lineages, models the fact that methylation patterns that affect gene expression can be inherited with certain variability [ 14 — 17 ].

Inheritance in the pump efficiency ε I is implemented in an analogous way, but using the corresponding Gaussian distribution G μ ε , σ ε. However, since we are assuming that changes in β 0 are epigenetic whereas those in ε I are genetic, the time-scales at which significant modifications in these parameters occur, are very different.

For it is known that phenotypic modifications due to epigenetic changes happen at rates at least one order of magnitude faster than those due to genetic changes [ 31 ].

Among the implications of using such small variances are that the changes in gene expression and pump efficiency between mother and daughter cells occur gradually. We also implemented for σ β a uniform distribution between 0 and 10, which allows abrupt changes in gene expression between the mother and daughter cells.

However, when this type of abrupt changes are allowed in σ β , adaptive resistance is not observed see S1 Text and S6 Fig. We do not know, based on experimental measurements, which of the two mechanisms mentioned above i. uniform vs Gaussian randomness is more compatible with the effect caused by methylation.

But, as we will see in the next section, our model predicts that when Gaussian distributions with small variances are used, adaptive resistance emerges, which is not the case for uniform distributions see S1 Text and S6 Fig. In order to quantify the effect that each type of inheritance has on the emergence of the resistance phenotype, we implemented four different scenarios: Control simulation: There is no inheritance, only variability.

The distributions G μ β , σ β and G μ ε , σ ε remain the same for all the cells in the population and throughout generations. Genetic inheritance: Mother-daughter correlations are implemented only in the pump efficiency ε I but not in the transcription rate β 0.

Epigenetic inheritance: Mother-daughter correlations are implemented only in the transcription rate β 0 but not in the pump efficiency ε I.

Mixed inheritance: Mother-daughter correlations are implemented in both the transcription rate β 0 and the pump efficiency ε I.

The synthesis and functioning of efflux pumps are associated with an energetic cost that must be taken into account. First, the pumps are very unspecific on its substrates [ 21 , 32 , 33 ]. Thus, in addition to antibiotics, they expel metabolites necessary for cell growth and division [ 34 ].

For instance, the acrAB-tolC efflux pump, is known to recognize a broad spectrum of chemicals. It also has a biased affinity towards phenolic rings, which are not only constituents of inducers of the system such as salicylic acid, but also of amino acids such as tyrosine [ 32 , 35 ].

Second, the synthesis of the pumps themselves large protein complexes and their functioning consume energy [ 9 , 32 , 35 ]. Therefore, it is reasonable to assume that the production and functioning of the pumps will slow down cell growth.

This assumption is supported by experimental observations indicating that over-expression of efflux pumps is correlated with both high levels of resistance and decreased growth [ 18 , 36 , 37 ]. In our model we set this cost by making the internal concentration of nutrient in each cell depend inversely on the amount of pumps see Eq.

The net result is a slowdown of the cell division rate, because a minimum internal nutrient concentration is required for division to happen. Thus, when the internal concentration of nutrients reaches a certain threshold θ F , the cell divides consuming the nutrient load, F.

Clearly, the division time the time it takes to reach the threshold θ F depends on the amount of pumps, which in turn depends on the transcription rate β 0 and the concentration of inducer see S1 Text and S7 Fig.

We have also included cell death in our population model. In order for the cell to survive, the efflux pumps need to keep the internal antibiotic concentration below the lethal level θ I. Whenever this threshold is reached, the cell dies and it is removed from the population. As in the experiments reported in Refs.

Thus, after M shocks the external antibiotic concentration will be. After each antibiotic shock, indicated by downward arrows in Fig. As can be observed in Fig. By contrast when epigenetic inheritance is not present, every cell in the population dies after the first shock.

The above results show that in our model variability alone is not enough for the emergence of adaptive resistance Fig. Analogously, genetic inheritance, which essentially consists of mother-daughter correlations occurring at long time scales, cannot give rise by itself to adaptive resistance either Fig.

This figure shows tracking plots of populations growing in successively increasing concentrations of antibiotic. For each cell the concentration of Activator is plotted at constant time intervals dots. The four panels correspond to the four different inheritance scenarios mentioned in the main text.

A Only epigenetic inheritance is implemented. B Mixed Inheritance. C Only genetic inheritance and D control no inheritance. The inset in A shows a zoomed in representation of the tracking plot, where one cell lineage is followed as it goes through several cell divisions and deaths.

Since dead cells are removed immediately from the population, their expression is no longer visible and their curves terminate abruptly causing a step-like structure. Note that high levels of resistance can be achieved only when there is epigenetic inheritance A and B.

Otherwise, the entire population dies after the first shock C and D. For such adaptive resistance to emerge, short-term mother-daughter correlations in the transcription rate β 0 of the EPRN operon need to be implemented in the model. Note that when both genetic and epigenetic inheritance are present Fig.

It is important to mention that if the antibiotic shocks occur at high frequencies for instance less than 10 generations between two successive shocks , or if each antibiotic shock is much more intense e. twice or more than the previous one, we observe no surviving cells whatsoever in any of the four scenarios.

It is also worth noting that if a discrete distribution for β 0 with 40 different values is used instead of a continuous Gaussian, the same qualitative results are obtained, as can be seen in S8 Fig. Therefore, adaptive resistance occurs even in the presence of moderate variability in gene expression, as long as there are mother-daughter correlations in such variability.

So far, the difference between genetic and epigenetic inheritance consists on one hand, in the time scales at which these two processes produce phenotypic changes in the population, and on the other hand in the parameters they affect. Genetic inheritance affects the pump efficiency ε I whereas epigenetic inheritance affects the transcription rate β 0.

Another important difference is that changes caused by genetic mutations are very unlikely to be reversible whereas epigenetic changes are much more likely to be reversible [ 31 , 38 ].

To test if our model can reproduce the experimentally observed reversibility, we replicate the simulations described in the previous section where levels of resistance are ramped higher for the mixed scenario.

But now, after several rounds of selection, we remove the external antibiotic and allow the cells to grow and divide without stress. The population size decreases exponentially each time an antibiotic shock is applied.

Note that when the antibiotic is removed the population growth returns to its wild-type behavior. These results are qualitatively similar to those observed experimentally [ 1 , 3 — 8 , 9 ]. However, this fact does not necessarily mean that the cells return to their wild type levels of susceptibility.

For the cells that have reversed back to a sensitive phenotype could still have very high values of transcription rate, β 0 , and this high rate would imply that as soon as the antibiotic is applied again, the activator and the efflux pumps will be produced rapidly and at high concentrations.

At this stage, most of the cells would be able to survive easily almost any antibiotic shock making the system non-reversible. A This tracking plot shows that the expression of the activator increases while the antibiotic shocks are applied as in Fig.

Then, when the antibiotic is removed indicated by the tilted black arrow , the expression of the activator decreases abruptly and eventually reaches its basal level. B Size of the population as a function of time for the same simulation as in A. After each antibiotic shock small black arrows the population size decreases exponentially and the recovery time becomes longer with each shock.

After the antibiotic is removed tilted black arrow the population comes back again to its wild-type WT growth rate. Note that the average increases while the shocks are applied and then gradually comes back to small values when the antibiotic is removed.

Error bars indicate the standard deviation. It can be observed that the standard deviation increases with the antibiotic stress. The panels below show the full distribution G μ β , σ β at three different times: before any antibiotic is introduced circle ; after several antibiotic shocks star ; after a long period of time without antibiotic line.

The only way for the population to truly reverse to its wild-type condition and become susceptible again is to return to their initial distribution G μ β , σ β , which is centered at low values of β 0.

We expect this to happen because cells with a small β 0 duplicate faster than cells with large β 0 see S1 Text and S7 Fig. Since the values of β 0 are correlated across generations, cells with faster division rates low β 0 will eventually dominate the population, shifting the distribution G μ β , σ β towards the low β 0 region.

Note that μ β increases as the antibiotic concentration is ramped higher. Then, when the external antibiotic is removed the average transcription rate across the population μ β decreases gradually, reaching the same value as in the original wild-type population.

The lower panels in Fig. But then again, when the antibiotic is removed, the distribution eventually returns to its initial configuration. In our model the time-scale to produce a phenotypic change due to genetic mutations is one order of magnitude larger than that needed to produce a phenotypic change due to epigenetic modifications.

Thus, to observe any significant increase in resistance produced by changes in the pump efficiency we need to run the simulation for a longer time. Interestingly, by doing this we obtain a nonreversible resistance, first driven by our mechanism of epigenetic inheritance which is reversible , and then fixed by genetic variation and inheritance of the pump efficiency.

To observe this phenomenon, which can be considered analogous to genetic assimilation [ 39 , 40 , 41 ], we performed numerical experiments similar to the ones presented in the previous sections, where the population is first induced with M antibiotic shocks.

The difference now is that we will let the population be in contact with the antibiotic for a very long time before removing it. A similar measure was used in [ 3 ]. In each case, the arrows indicate the time at which the antibiotic is removed.

The results depicted in Fig. The blue curve deserves special attention. After this, the antibiotic concentration was kept constant until the time indicated by the blue arrow, at which the antibiotic was removed.

Note that the RI keeps increasing even during the interval of steady antibiotic concentration. Note also that the final RI stationary value reached after the antibiotic is removed is five times larger for the blue curve than for all the other curves.

It is worth noting that the black curve, corresponding to a control population growing in the absence of antibiotic, remains close to the initial low basal level throughout the entire simulation. Therefore, in our model antibiotic resistance occurs only as a response to the selective pressure imposed by the antibiotic and not by random genetic drift.

A Resistance Index RI as a function of time for populations induced with M antibiotic shocks. The different curves correspond to different values of M , except by the black one which corresponds to a control population growing with no antibiotic. B Blow up showing the first generations.

For each curve, the corresponding arrow indicates the time at which the antibiotic is removed. In the case of the blue curve, the asterisk indicates the time at which the last antibiotic shock is applied, after which the antibiotic concentration is kept constant.

C Blow up of the last part of the simulation showing the point at which the antibiotic is removed from the population corresponding to the blue curve.

It can be observed that in this case the final stationary value of the RI is about five times higher than that of the control population. D Evolution of the average transcription rate μ β and the average pump efficiency μ ε for the population corresponding to the blue curve.

Notice that as soon as the antibiotic concentration is kept constant, μ β starts decreasing whereas μ ε keeps rising until the antibiotic is completely removed.

This shows that the evolutionary process does not reach a stationary state or fixed point in the presence of antibiotic. It is important to mention that the increase in the basal level of the RI shown in Fig. Indeed, Fig. From Fig. However, as soon as the antibiotic concentration is kept constant, even at a high value, the average transcription rate μ β starts decreasing and reaches its initial low value at the end of the simulation.

Contrary to this, the average pump efficiency μ ε keeps rising as long as there is antibiotic in the environment, reaching a steady value only when the antibiotic is removed.

Thus, exposing the population to a high antibiotic concentration for a long time produces a non-reversible shift in the pump efficiency distribution P ε , permanently increasing the level of resistance of the population. It is also important to emphasize the difference between the survival rate SR and the resistance index RI.

The former is defined as the fraction of cells that survive an induction, and this fraction ranges from 0 if no cell survives to 1 if all cells survive. On the other hand, the RI is the value of the antibiotic concentration at which the SR is 0.

Therefore, the RI does not have to be between 0 and 1. Actually, its value depends on the units used to measure the antibiotic concentration in our case we use arbitrary units and the capability of the population to resist the antibiotic. This capability, in turn, depends on the way β 0 and ε I are distributed across the population.

In each cell, these parameters determine the fixed points of the system only one fixed point exists for a given combination of β 0 and ε I in the range of concentrations explored in this work, see S1 Text and S9 Fig.

The results presented in Fig. Adaptive resistance in bacteria is observed after subjecting a population to gradual increments of antibiotic concentration. Regardless of the level of resistance reached through this process, which can be very high , the resistance disappears after a few generations in the absence of antibiotic.

Previous studies have independently identified epigenetic inheritance and phenotypic heterogeneity as important components involved in the emergence of adaptive resistance [ 1 , 3 , 4 , 6 , 7 , 8 , 11 ], but their role has never been evaluated quantitatively. Additionally, the molecular origin of reversibility observed in adaptive resistance has remained unclear.

In this study we present a theoretical framework that identifies the essential mechanisms for the emergence, evolution and reversibility of adaptive resistance.

We constructed a single-cell dynamic model of a prototypic efflux pump regulatory network EPRN that incorporates the most updated information available in the literature.

We calibrated this model with experimental observations for wild type and mutant E. coli strains. We then grew a population of such single cells with growth dynamics obeying simple rules such as division, death, variability and inheritance of gene expression patterns.

For each cell in the population we compute their EPRN temporal dynamics.

How Antibiotic Resistance Happens | CDC Thin Solid Films — Adaptife Adaptive antimicrobial materials resistance Adaptife daptomycin Adaptivw treatment Adaptive antimicrobial materials vancomycin-resistant Enterococcus antimicrobiwl infection. Karthik K, Dhanuskodi S, Gobinath C et Liver detox diets Dielectric and antibacterial studies of microwave assisted calcium hydroxide nanoparticles. The prototypical example of successful anti-resistance therapeutics are the β-lactamase inhibitors. Submitted 19 Oct Extended spectrum β-lactamases ESBL hydrolyze oxyimino-aminothiazolyl cephalosporins cefotaxime, cefuroxime, cefepime, ceftriaxone and ceftazidine as well as penicillins and other cephalosporins, excluding cephamycins Livermore and Brown,
Introduction Antimicroobial Zhang. Mechanisms of ciprofloxacin resistance Adatpive pseudomonas aeruginosa: New approaches to an old problem. Promising anti-resistance adjuvant therapeutics and targets will be described, and key remaining challenges highlighted. Reardon, S. Fecal microbiota transplantation: an update on clinical practice. depending on the organism.
aeruginosa antjmicrobial classified as a priority Adaptivve pathogen by the Mateeials Health Organisation, and Adaptive antimicrobial materials drugs are urgently needed, due Fat burn support the emergence of multidrug-resistant MDR strains. Adqptive nosocomial pathogens such as P. aeruginosa pose unwavering and increasing threats. Antimicrobial stewardship has been a challenge during the COVID pandemic, with a majority of those hospitalized with SARS-CoV2 infection given antibiotics as a safeguard against secondary bacterial infection. This increased usage, along with increased handling of sanitizers and disinfectants globally, may further accelerate the development and spread of cross-resistance to antibiotics.

Author: Shasar

5 thoughts on “Adaptive antimicrobial materials

  1. Ich denke, dass Sie nicht recht sind. Ich kann die Position verteidigen. Schreiben Sie mir in PM.

Leave a comment

Yours email will be published. Important fields a marked *

Design by